证券代码：688114 证券简称：华大智造 公告编号：2025-060 深圳华大智造科技股份有限公司 关于就 CoolMPS 测序技术签署授权许可协议 暨受让与关联方相关共有专利并进行授权收入分成 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 技术相关专利权，并按《转让协议》的约定支付授权费用。 交易标的：MGI LLC、CGI 与 Swiss Rockets 交易的标的为 CoolMPS 测序技 术相关专利、技术秘密及商标在亚太及大中华（包括中国大陆、香港、澳门和台 湾）以外区域的全球范围内的独占许可；以及通用测序技术相关专利、技术秘密 及商标在上述区域的普通许可。 公司与关联方华大研究院交易的标的为公司与华大研究院共同持有的部分 CoolMPS 测序技术及 stLFR 建库技术相关专利权（以下简称"标的专利"）。 交易金额：MGI LLC、CGI 与 Swiss Rockets 交易的首付款、里程碑付款及 销售分成，根据《许可协议》，本次交易正常履约至独占授权期满公司合计可获 得不低于 1.2 亿美元的授权许可费 ...

一、 关于公司就 CoolMPS 测序技术签署授权许可协议暨受让与关联方相关共有专 利并进行授权收入分成事项的审查意见 深圳华大智造科技股份有限公司 第二届董事会独立董事 2025 年第三次专门会议的审查意见 我们作为深圳华大智造科技股份有限公司（以下简称"公司"）的独立董事，根 据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司独立董事管理办 法》《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律 监管指引第 1 号——规范运作》等法律法规、上海证券交易所业务规则以及《公司章 程》和《独立董事工作制度》等公司内部制度的相关规定，召开第二届董事会独立董 事 2025 年第三次专门会议，基于独立判断的立场，在仔细审阅了《关于就 CoolMPS 测序技术签署授权许可协议暨受让与关联方相关共有专利并进行授权收入分成的议案》 的相关文件后，经审慎分析发表如下审查意见： 2025 年 10 月 12 日 1 公司此次对外独占授权 CoolMPS 测序技术及受让由公司与关联方深圳华大生命科 学研究院共同持有的部分 CoolMPS 测序技术及 stLFR 建库技术相关专利权，并按《技 术转让（ ...

证券代码：688114 证券简称：华大智造 公告编号：2025-063 深圳华大智造科技股份有限公司 关于召开2025年第四次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 股东大会召开日期：2025年10月28日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 一、 召开会议的基本情况 （一） 股东大会类型和届次 2025年第四次临时股东大会 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票 相结合的方式 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互 联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 （六） 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投 票，应按照《上海证券交易所科创板上市公司 ...

证券代码：688114 证券简称：华大智造 公告编号：2025-062 深圳华大智造科技股份有限公司 本议案经公司监事会审议通过后，尚需提交公司股东大会审议批准。 特此公告。 深圳华大智造科技股份有限公司 第二届监事会第十六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳华大智造科技股份有限公司（以下简称"公司"）第二届监事会第十六 次会议于 2025 年 10 月 12 日以现场结合通讯方式召开。会议通知已于 2025 年 10 月 9 日通过邮件的方式送达各位监事。本次会议应出席监事 3 人，实际出席 监事 3 人。会议由监事会主席周承恕先生主持。会议召开符合有关法律、行政法 规、部门规章和《公司章程》的规定。出席会议的监事对以下议案进行了认真审 议并做出了如下决议： 一、审议通过《关于就 CoolMPS 测序技术签署授权许可协议暨受让与关联 方相关共有专利并进行授权收入分成的议案》 经审议，监事会认为：公司本次与 Swiss Rockets AG 的授权许可交易及与深 圳华大生命科学研究院的关联交 ...

证券代码：688114 证券简称：华大智造 公告编号：2025-061 深圳华大智造科技股份有限公司 第二届董事会第十七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 公司全资子公司 MGI US LLC（以下简称"MGI LLC"）及 Complete Genomics,Inc（. 以下简称"CGI"）与 Swiss Rockets AG（以下简称"Swiss Rockets"） 签署《授权许可协议》（以下简称《许可协议》），将公司的 CoolMPS 测序技 术（以下简称"CoolMPS"或"无损碱基测序技术"）及通用测序技术（含 stLFR 和 cLFR 等所涉及测序仪、芯片及建库试剂等产品所需底层技术，以下简称"通 用测序技术"）有偿授权给 Swiss Rockets。在亚太及大中华区（包括中国大陆、 香港、澳门和台湾）以外区域的全球范围内，Swiss Rockets 将获得 CoolMPS 测 序技术相关的专利、技术秘密（Know-How）及商标的独占许可，并在上述区域 内获得通 ...

Core Viewpoint - The signing of the licensing agreement between the company's wholly-owned subsidiary MGILLC, CGI, and SwissRockets is expected to have a positive impact on the company's future performance, enhancing its global commercialization and profitability [1] Group 1 - The company announced the signing of a licensing agreement with SwissRockets [1] - The agreement involves the company's wholly-owned subsidiary MGILLC and CGI as joint transferors [1] - The company anticipates that the agreement will positively influence its future performance [1]

Core Viewpoint - 华大智造's stock price has shown significant fluctuations, with a year-to-date increase of 49.35%, but recent trading indicates a decline in market performance and net outflow of funds [1][2]. Financial Performance - As of June 30, 2025, 华大智造 reported a revenue of 1.114 billion yuan, a year-on-year decrease of 7.90%, while the net profit attributable to shareholders was -104 million yuan, an increase of 65.28% compared to the previous year [2]. - The company has distributed a total of 150 million yuan in dividends since its A-share listing [3]. Stock Market Activity - 华大智造's stock price decreased by 2.01% on October 10, 2023, trading at 69.88 yuan per share with a total market capitalization of 29.106 billion yuan [1]. - The stock has appeared on the龙虎榜 twice this year, with the most recent instance on March 4, 2023, where it recorded a net buy of -44.7653 million yuan [2]. Shareholder Structure - As of June 30, 2025, the number of shareholders increased by 7.64% to 13,500, with an average of 15,766 shares held per person, a decrease of 7.09% [2]. - Major shareholders include 华夏上证科创板50成份ETF and 易方达上证科创板50ETF, with notable changes in their holdings [3].

Core Viewpoint - The domestic innovative drug industry is transitioning from a follower to FIC/BIC innovation, supported by engineer dividends, abundant clinical resources, and favorable policies, indicating a qualitative improvement as it enters the 2.0 era [1][2] Group 1: Industry Development - The innovative drug sector is expected to benefit from policy reforms in payment systems, enhancing the profitability of innovative drug companies as they commercialize domestic products [2] - The upcoming ESMO conference in mid-October is anticipated to provide new investment opportunities through the release of relevant clinical data and business development (BD) activities [2] Group 2: Investment Climate - The investment landscape has improved since early this year, with a notable reversal in the financing trend for the innovative drug industry, particularly in the A/H market [3] - The recovery of IPO projects and financing activities in the secondary market is expected to positively impact investment data in Q3, benefiting domestic CROs and upstream research sectors [3] Group 3: Policy Support - Continuous advancement of commercial medical insurance policies since 2025 is likely to accelerate payment system reforms, easing supply-demand conflicts and supporting domestic innovation [4] - Fiscal policy enhancements are expected to increase market interest in domestic medical equipment stocks [4] Group 4: Target Companies - A-share targets include: BeiGene (688235.SH), Hengrui Medicine (600276.SH), Kelun Pharmaceutical (002422.SZ), WuXi AppTec (603259.SH), Tigermed (300347.SZ), New Industry (300832.SZ), BGI Genomics (688114.SH), Huatai Medical (688617.SH), and Dian Diagnostics (300244.SZ) [5] - H-share targets include: Kelun Biotech (06990), CSPC Pharmaceutical (01093), China Biologic Products (01177), CanSino Biologics (09926), WuXi Biologics (02269), Junshi Biosciences (01877), and Zai Lab (09688) [5]

Core Viewpoint - 华大智造's stock price has shown significant growth this year, with a 50.82% increase, indicating strong market interest and potential investment opportunities [2]. Financial Performance - As of June 30, 2025, 华大智造 reported a revenue of 1.114 billion yuan, a year-on-year decrease of 7.90%, while the net profit attributable to shareholders was -104 million yuan, reflecting a 65.28% increase compared to the previous year [2]. - The company has distributed a total of 150 million yuan in dividends since its A-share listing [3]. Stock Market Activity - 华大智造's stock price increased by 2.02% on October 9, 2023, reaching 70.57 yuan per share, with a trading volume of 161 million yuan and a turnover rate of 0.56% [1]. - The stock has appeared on the龙虎榜 twice this year, with the most recent appearance on March 4, 2023, where it recorded a net buy of -44.7653 million yuan [2]. Shareholder Structure - As of June 30, 2025, the number of shareholders increased by 7.64% to 13,500, with an average of 15,766 circulating shares per person, a decrease of 7.09% [2]. - Major institutional shareholders include 华夏上证科创板50成份ETF and 易方达上证科创板50ETF, with changes in their holdings noted [3].

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Views - The company reported a year-on-year revenue decline of 7.90% for the first half of 2025, with total revenue of 1.114 billion yuan and a net loss attributable to shareholders of 104 million yuan. However, the second quarter of 2025 showed improvement with revenue of 659 million yuan, a year-on-year decline of only 2.93%, and a net profit of approximately 29.77 million yuan, marking a year-on-year increase of 130.62% [5][6] Summary by Sections Financial Performance - In Q1 2025, the company achieved revenue of 455 million yuan (yoy -14.26%), while Q2 2025 saw revenue of 659 million yuan (yoy -2.93%). The net profits for Q1 and Q2 were -133 million yuan and 29.77 million yuan respectively, indicating a return to profitability in Q2 2025 [6] - The company’s expense ratios significantly decreased in Q2 2025, with sales, management, and R&D expense ratios at 25.71%, 16.39%, and 20.57% respectively, showing substantial reductions both year-on-year and quarter-on-quarter [6] Product and Market Development - The company’s full-length sequencing business generated revenue of 894 million yuan in H1 2025, a year-on-year decline of 12.15%. Instrument revenue was 298 million yuan (yoy -23.18%), while reagent revenue was 555 million yuan (yoy -6.30%). This decline was attributed to intensified industry competition and strategic price adjustments [7] - The global sales of the company’s sequencing instruments exceeded 700 units in H1 2025, a year-on-year increase of 60.35%, marking a historical high for the same period. The company has also entered the mass production phase for nanopore sequencers, adding nearly 50 new installations [7] - As of August 15, 2025, the company had approximately 900 million yuan in orders on hand, with 700 million yuan specifically for the full-length sequencing business, indicating a robust order backlog [7] International Business Performance - In H1 2025, the company’s sequencing instrument revenue in the Asia-Pacific region was 80 million yuan, a year-on-year decline of 29%, primarily due to geopolitical conflicts affecting procurement processes. Conversely, revenue in the Europe and Africa region was 140 million yuan, a year-on-year increase of 3%, driven by local operational acceleration and project collaborations [8] - Revenue in the Americas region was 80 million yuan, a year-on-year decline of 3%, influenced by significant cuts in research funding and regional instability [8] Future Projections - The company is expected to achieve revenues of 2.824 billion yuan, 3.341 billion yuan, and 3.943 billion yuan for the years 2025 to 2027, with year-on-year growth rates of -6.3%, 18.3%, and 18.0% respectively. The net profit attributable to shareholders is projected to be -98 million yuan, 50 million yuan, and 162 million yuan for the same period, with significant year-on-year growth anticipated [9]